Abstracts tagged "etanercept"

Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Eimear Savage¹, David McCormick¹, Stephen McDonald¹, Michael Stevenson², Owen Moore³ and Andrew Cairns⁴, ¹Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, ²Medical Statistics, Centre for Public Health., Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT12 6BJ, Northern Ireland, ³Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁴Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom
Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population. Patients often report increasing joint pain with…
Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…
Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Kirsten Minden¹, Klaus Tenbrock², Gerd Horneff³ and Hans-Iko Huppertz⁴, ¹Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ²University Aachen, Aachen, Germany, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Prof. Hess Childrens Hospital, Bremen, Germany
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Michael E. Weinblatt¹, Joan M. Bathon², Michele Hooper³, Bojena Bitman⁴, Yue Yang⁵, David H. Collier⁶, James Chung⁷ and Mark C. Genovese⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Amgen Global Safety, Amgen Inc., Thousand Oaks, CA, ⁴Amgen, Inc., San Francisco, CA, ⁵Assent Consulting, South San Francisco, CA, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen, Thousand Oaks, CA, ⁸Division of Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Ying-Ming Chiu¹, Chao-Hsiung Tang², Sheng-Tzu Hung³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Hsiao-Yi Lin⁵, ¹Changhua Christian Hospital, Changhua City, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Formosa Biomedical Technology Corp., Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…
Abstract Number: 2184 • 2013 ACR/ARHP Annual Meeting
Application Of The Bonexpert Method For Bone Age and Bone Health Assessment In Patients With Juvenile Idiopathic Arthritis
Charlotte M. Nusman¹, Janneke Anink², Lisette W.A. van Suijlekom-Smit², Marion A.J. van Rossum³, Mario Maas⁴ and Rick R. van Rijn⁴, ¹Department of Radiology, Academic Medical Center, Amsterdam, Netherlands, ²Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ³Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ⁴Radiology, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Both the maturation of bone and its mineral density are affected by chronic inflammation in juvenile idiopathic arthritis (JIA). Bone age is in most…
Abstract Number: 471 • 2013 ACR/ARHP Annual Meeting
Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission
Joaquín Borrás-Blasco¹, Antonio Gracia-Pérez², Dolores-Elvira Casterá¹, J. Dolores Rosique-Robles¹, Javier Abad¹ and Alejandro González Álvarez³, ¹Pharmacy Service, Hospital de Sagunto, Sagunto, Spain, ²Rheumatology Service, Hospital de Sagunto, Sagunto, Spain, ³Hospital Obispo Polanco, Teruel, Spain
Etanercept 25 mg once weekly program for rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients in sustained clinical and radiological remissionBackground/Purpose: Etanercept 50mg/week (ETN50) has…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Grant W. Cannon¹, Scott L. DuVall², Candace L. Hayden³, Liron Caplan⁴, Jeffrey R. Curtis⁵, Kaleb Michaud⁶, Ted R. Mikuls⁷, Andreas M. Reimold⁸, David H. Collier⁹, George Joseph⁹, David J. Harrison⁹ and Brian C. Sauer¹⁰, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³Epidemiology, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁵Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Epdemiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…
Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting
Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Antonio da Silva¹, Ulrich Kronthaler¹, Cornelius Fritsch², Johann Poetzl³, Adelheid Rohde⁴, Anastassia Papandrikopoulou⁵, Hans-Peter Hofmann⁶ and Jan Marinus Visser¹, ¹Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ²Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland, ³Bioanalytics, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, ⁴Characterisation, Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, ⁵Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ⁶Pre-clinical, Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany
Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis
Bernard Combe¹, Urs Kerkmann², Fiona Brock³ and Gaia Gallo², ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Pfizer Europe, Rome, Italy, ³Quanticate, Hitchin, Hertfordshire, United Kingdom
Background/Purpose: Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…
Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Edward Bernton¹ and Valerie Lowe², ¹Protalex Inc., Summit, NJ, ²Washington Biotechnology, Inc., Baltimore, MD
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…
Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Tamas Constantin¹, Ivan Foeldvari², Jelena Vojinovic³, Gerd Horneff⁴, Ruben Burgos-Vargas⁵, Irina Nikishina⁶, Jonathan Akikusa⁷, Tadej Avcin⁸, Jeffrey Chaitow⁵, Elena Koskova⁹, Bernard Lauwerys¹⁰, Jack Bukowski¹¹, Chuanbo Zang¹², Joseph Wajdula¹², Deborah Woodworth¹², Bonnie Vlahos¹³, Alberto Martini¹⁴ and Nicolino Ruperto⁵, ¹Semmelweis University, Budapest, Hungary, ²Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ³Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, ⁴Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵PRINTO, Genoa, Italy, ⁶Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁷Rheumatology, Royal Childrens Hospital, Parkville, Australia, ⁸The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹⁰Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc., Collegeville, PA, ¹³Department of Specialty Care, Pfizer Inc., Collegeville, PA, ¹⁴Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Heather Jones¹, Annette Szumski² and Andrew S. Koenig³, ¹Pfizer Inc., Collegeville, PA, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].